Affiliation:
1. Epigenetics of Aging, Department of Dermatology and Allergy, TUM School of Medicine, Munich Institute of Biomedical Engineering (MIBE), Technical University of Munich (TUM), 85748 Garching, Germany
2. Unit of Bologna, CNR Institute of Molecular Genetics “Luigi Luca Cavalli-Sforza”, 40136 Bologna, Italy
3. IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
Abstract
Hutchinson–Gilford progeria syndrome (HGPS) is a rare genetic disease that causes premature aging symptoms, such as vascular diseases, lipodystrophy, loss of bone mineral density, and alopecia. HGPS is mostly linked to a heterozygous and de novo mutation in the LMNA gene (c.1824 C > T; p.G608G), resulting in the production of a truncated prelamin A protein called “progerin”. Progerin accumulation causes nuclear dysfunction, premature senescence, and apoptosis. Here, we examined the effects of baricitinib (Bar), an FDA-approved JAK/STAT inhibitor, and a combination of Bar and lonafarnib (FTI) treatment on adipogenesis using skin-derived precursors (SKPs). We analyzed the effect of these treatments on the differentiation potential of SKPs isolated from pre-established human primary fibroblast cultures. Compared to mock-treated HGPS SKPs, Bar and Bar + FTI treatments improved the differentiation of HGPS SKPs into adipocytes and lipid droplet formation. Similarly, Bar and Bar + FTI treatments improved the differentiation of SKPs derived from patients with two other lipodystrophic diseases: familial partial lipodystrophy type 2 (FPLD2) and mandibuloacral dysplasia type B (MADB). Overall, the results show that Bar treatment improves adipogenesis and lipid droplet formation in HGPS, FPLD2, and MADB, indicating that Bar + FTI treatment might further ameliorate HGPS pathologies compared to lonafarnib treatment alone.
Funder
Deutsche Forschungsgemeinschaft
Progeria Research Foundation
Reference105 articles.
1. Association of Lonafarnib Treatment vs. No Treatment with Mortality Rate in Patients with Hutchinson-Gilford Progeria Syndrome;Gordon;JAMA,2018
2. Phenotype and course of Hutchinson-Gilford progeria syndrome;Merideth;N. Engl. J. Med.,2008
3. Hutchinson–Gilford progeria syndrome;Ullrich;Handbook of Clinical Neurology: Neurocutaneous Syndromes,2015
4. Gordon, L.B., Brown, T.W., and Collins, F.S. (2011). Gene Reviews, Springer.
5. Progeria Research Foundation (2022, January 24). PRF by the Numbers. Available online: https://www.progeriaresearch.org/quick-facts.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献